YAP/TAZ-Hippo pathway mediates the tumorigenesis of various cancers through post-translational modification represented by ubiquitination
Open Access
- 3 February 2025
- journal article
- editorial
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-4
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shaanxi Province (S2024-JC-QN-1771)
This publication has 31 references indexed in Scilit:
- Structural and Biochemical Insights into the Mechanism of Action of the Clinical USP1 Inhibitor, KSQ-4279Journal of Medicinal Chemistry, 2024
- N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradationGastric Cancer, 2023
- Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markersEBioMedicine, 2023
- OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancerOncogene, 2022
- Deubiquitinases: From mechanisms to their inhibition by small moleculesMolecular Cell, 2022
- Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trialInvestigational New Drugs, 2021
- In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy targetCell, 2021
- The Hippo-TAZ axis mediates vascular endothelial growth factor C in glioblastoma-derived exosomes to promote angiogenesisCancer Letters, 2021
- Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaInvestigational New Drugs, 2020
- The Hippo pathway and human cancerNature Reviews Cancer, 2013